Results 11 to 12 of about 15 (12)

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial. [PDF]

open access: yesSignal Transduct Target Ther
Wu J   +23 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy